BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CV&Met Disease Analysis: Chronic Heart Failure

June 03, 2022

The chronic heart failure (CHF) market is expected to grow significantly over the next 10 years across the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). The CHF market has predominantly been saturated with generics, which has limited the market revenue; however, there are a growing number of late-stage pipeline therapies, which, combined with the rising disease prevalence, will be major drivers of market growth. 

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are beginning to alter the existing CHF treatment landscape, as seen in updates that have recently been made to treatment guidelines in the US, EU, and Japan, which now recommend the use of SGLT-2 inhibitors in the first line, in combination with drugs targeting the renin-angiotensin-aldosterone system, beta blockers, and mineralocorticoid receptor antagonists. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Chronic Heart Failure - Preserved Ejection Fraction (Chronic HFpEF)
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Back to the top Back to the top